Imara M&A

Pipeline & Discovery Programs Parallel lead product candidates: Program ELVN-001 ELVN-002 Target Target 1 Target 2 Target 3 Target Target 4 BCR-ABL HER2 & mutants The following table highlights discovery programs that we are prioritizing: Target ID / Validation Disease Solid tumors Solid tumors Solid tumors Disease Solid tumors CML NSCLC, other solid tumors Differentiation Highly selective w/T3151 activity EGFR sparing, pan-mutant Differentiation No approved therapies CNS penetration No approved therapies No approved therapies Lead Optimization CML = Chronic myeloid leukemia. CNS = Central nervous system. IND = Investigational new drug. NSCLC = Non-small cell lung cancer IND-Enabling Lead Identification Phase 1 Lead Optimization Phase 2 IND-Enabling Phase 3 Phase 1 Next Milestone Early Phase 1 Data IND Filing Phase 2 Milestone Expected YE 2023 4Q 2022 Phase 3 Expected to make a product candidate nomination for our 3rd program by 1H 2023 8

View entire presentation